41
Participants
Start Date
December 21, 2018
Primary Completion Date
November 29, 2022
Study Completion Date
November 29, 2022
Inhaled treprostinil solution
Inhaled treprostinil solution per dose and schedule specified in the arm
Mount Sinai Medical Center, New York
Albany Medical Center, Albany
University of Rochester Medical Center, Rochester
Allegheny General Hospital, Pittsburgh
University of Pittsburgh Medical Center, Pittsburgh
University of Maryland Medical Center, Baltimore
Inova Fairfax Hospital, Falls Church
Pulmonary Associates of Richmond, Inc., Richmond
Carilion Clinic, Roanoke
University of North Carolina at Chapel Hill, Chapel Hill
Medical University of South Carolina, Charleston
Georgia Clinical Research, Austell
Pulmonary & Critical Care of Atlanta, Atlanta
St. Vincent's Lung, Sleep, and Criticial Care Specialists, Jacksonville
Mayo Clinic - Jacksonville, Jacksonville
University of Miami Hospital, Miami
St. Francis Sleep Allergy & Lung Institute, Clearwater
Lady Davis Carmel Medical Centre, Haifa
The University of Alabama at Birmingham, Birmingham
Kentuckiana Pulmonary Associates, Louisville
Cleveland Clinic, Cleveland
The Carl and Edyth Lindner Research Center at The Christ Hospital, Cincinnati
St. Vincent Medical Group, Inc., Indianapolis
Rabin Medical Center, Petah Tiva
Spectrum Health, Grand Rapids
University of Wisconsin School of Medicine and Public Health, Madison
University of Illinois Medical Center, Chicago
University of California Davis Medical Center, Sacramento
Hadassah-Hebrew University Hospital, Jerusalem
Brigham and Women's Hospital, Boston
Lead Sponsor
Collaborators (1)
Lung Biotechnology PBC
INDUSTRY
United Therapeutics
INDUSTRY